We found that both circulating effector Tfr (cTfr) and preTfr cells were significantly reduced at all measured time points in COVID-19 and early stages in sepsis in comparison to age-matched healthy controls (Fig. 1, E and F). This evidence concerns the gene TFRC and COVID-19.